Xtandi enzalutamide: Phase II data

Medivation reported data from an open-label, European Phase II trial in 67 patients with hormone-naïve prostate cancer showing that once-daily 160 mg oral Xtandi met the primary endpoint of PSA response rate at week 25. Specifically, 93% of patients achieved a reduction from baseline in PSA level of >=80% at week 25. The median reduction in PSA level from baseline to week 25 was 99.6%. Additionally, serum testosterone level increased by a mean of 114% from baseline to week 25. The most common treatment-related adverse events were gynecomastia, fatigue, nipple pain and hot flush. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. ...